Pharmacological Management of Anxiety Disorders: A Review of Current Drugs, Limitations and Emerging Therapies

Anxiety :

Anxiety is a feeling of fear, worry, nervousness or tension about something that may happen in the future it is called anxiety. this time most face anxiety Many people experience anxiety without realizing it. They might mistake physical or emotional stress for just a normal part of life, assuming it will pass on its own. However, leaving chronic anxiety unaddressed can lead to long-term effects, including persistent fatigue, weakened immune function, and increased difficulty managing stress in the future. Anxiety is one of the most common mental health conditions worldwide. It affects a person’s mood, thinking, behavior, and physical health. While normal fear helps us react to immediate danger, pathological anxiety is excessive, persistent, and interferes with daily life, sleep, concentration, and social relationships According to the WHO (ICD-11), Anxiety Disorders are characterized by:

• Excessive and Persistent Fear or Anxiety: The fear or anxiety is significantly out of proportion to the actual danger or threatening nature of the situation.
• Behavioral Disturbances: Individuals actively try to avoid situations, objects, or places that trigger their anxiety.
• Impairment in Daily Functioning: These symptoms cause significant distress or impairment in personal, family, social, educational, occupational, or other important areas of functioning.

Furthermore, recurrent panic attacks and chronic stress trigger the body's survival mode, often referred to as the 'fight-or-flight' response. During this state, elevated levels of stress hormones such as cortisol lead to an acute increase in blood glucose levels to supply immediate energy. This sustained physiological stress significantly impacts the hypothalamic-pituitary-adrenal (HPA) axis, which in turn disrupts the hypothalamic-pituitary-gonadal (HPG) axis responsible for regulating reproductive hormones (estrogen and progesterone). Consequently, this hormonal dysregulation can delay ovulation, ultimately resulting in an irregular or delayed menstrual cycle among affected females.

For example:

• Feeling nervous before an examination.
• Feeling worried before an interview.
• Feeling afraid before speaking in front of a large group

Causes:

feeling on edge, quick fatigue, difficulty concentrating, irritability, muscle tension, and sleep disturbances.

TYPES OF ANXIETY DISORDERS:

1. Generalized Anxiety Disorder (GAD) : Continuous, excessive worry about everyday events for at least 6 months.

2. Panic Disorder & Agoraphobia : Sudden, intense panic attacks with symptoms like chest pain, dizziness, and shortness of breath, leading to fear of crowded or open spaces where is difficult.

3. Phobias : Intense fear of specific objects (e.g., animals, heights, blood) or social situations.

4. Obsessive-Compulsive Disorder (OCD) : Repetitive thoughts (obsessions) that trigger repetitive actions (compulsions) to reduce stress.

5. PTSD & Acute Stress Disorder : Fear, avoidance, and re-experiencing traumatic memories after severe life event

Pathophysiology Of Anxiety:

Why Anxiety Happens : The Body and Brain

1. Chemical Imbalances in the Brain:

Different anxiety conditions are connected to imbalances in specific brain chemicals (neurotransmitters). For instance, worry and tension are often linked to the GABA system, panic is connected to fight-or-flight (noradrenergic) chemicals, and obsessive thoughts relate closely to serotonin. Other influences include genetics, daily stress, and hormone shifts.

2. An Overactive Alarm System:

i) People with heavy anxiety—like Generalized Anxiety Disorder (GAD)—have a brain region called the amygdala that acts like an overly sensitive smoke alarm. It reacts intensely to stress and potential threats.

ii) Normally, the front part of the brain (the prefrontal cortex) helps calm this alarm down, but in anxious individuals, this "brake system" doesn't work as well, leaving the body stuck in a state of high alert.

3. The Physical Toll:

Anxiety triggers the sympathetic nervous system, leading to high heart rates and tension, while lowering the calming parasympathetic nervous system activity (like lower heart rate variability).

4. Why Do People Worry So Much?

i) While people often think worrying helps them solve problems, research shows that verbal worrying actually keeps the body stressed and pumps out stress hormones like cortisol.

ii) Psychologically, worry acts as a shield against sudden, painful emotional shocks. By keeping themselves in a constant low-level state of worry, people feel like they are emotionally prepared for the worst so they won't be caught off guard.

General Symptoms:

• Restlessness

- shocks. By keeping themselves in a constant low-level state of worry, people feel

like they are emotionally prepared for the worst so they won't be caught off guard.

2. Proven Ways to Treat Anxiety

A. Medications

• Antidepressants (SSRIs & TCAs): These are the most common medications prescribed. They help rebalance brain chemicals over time and are standard treatments for panic, social anxiety, obsessive-compulsive disorder (OCD), and post-traumatic stress.
• MAOIs: Another type of antidepressant that is especially effective for social phobia, though certain types require strict changes in diet.
• Benzodiazepines: Medications like Xanax or Valium work quickly to stop severe anxiety or panic. However, doctors try to avoid long-term use because the body builds a tolerance to them, and stopping them can trigger difficult withdrawal symptoms.

B. Talk Therapy (Cognitive Behavioral Therapy - CBT)

• Therapy is just as effective as medication, but it often provides longer-lasting results with a lower chance of the anxiety returning.
• Exposure Therapy : Safely facing feared situations, memories, or physical sensations step-by-step until the brain learns they are not actually dangerous.
• Cognitive Restructuring : Learning to catch negative, catastrophic thoughts and replace them with realistic, balanced perspectives.
• Relaxation & Breathing : Practicing controlled breathing and muscle relaxation to calm down the physical fight-or flight response.

C. Combined Care & Self-Help

• Combining Pills and Therapy : Studies show that taking medication and doing therapy at the same time is usually no more effective in the long run than doing either one by itself. In fact, people who rely only on pills to feel better often struggle more if they try to stop taking them later.
• Self-Help Guides : Structured self-help books and guided programs with minimal therapist support have also been proven to help people overcome conditions like panic disorder.

Anti-Anxiety Drugs (Anxiolytics):

Anti-anxiety drugs are medicines used to reduce anxiety, fear, nervousness, restlessness and excessive worry basically anti anxiety are those drugs which used to treat anxiety. Anxiety is a feeling of fear or worry. It is normal in some situations, but when it becomes excessive and affects daily life, treatment may be required.

Anti-anxiety drugs are also called anxiolytic drugs.

Examples: Diazepam, Alprazolam, Lorazepam and Busiprone .

General Classification of Anti-Anxiety :

1. Benzodiazepines

- Diazepam, Lorazepam, Alprazolam, Clonazepam

2. Non-benzodiazepine anxiolytic

- Busiprone

3. Antidepressants used in anxiety

- SSRIs: Sertraline, Escitalopram, Fluoxetine

- SNRIs: Venlafaxine, Duloxetine

4. Antihistamines

- Hydroxyzine

5. Beta-blockers

- Propranolol — mainly for physical symptoms of performance an

1. Traditional & Established Pharmacotherapy

These are the foundational medications currently used in clinical practice, though they often carry limitations such as incomplete response rates or side effects

i. First-Line Agents (SSRIs and SNRIs) : Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors are standard treatments, though they can cause adverse effects like sexual dysfunction.

ii. Second-Line / Adjunctive Agents : Tricyclic Antidepressants (TCAs) and Monoamine Oxidase Inhibitors (MAOIs), which are less commonly used as first-line due to side-effect profiles.

iii. Rapid-Onset Sedatives (Benzodiazepines): Fast-acting medications that provide acute relief but carry severe risks of dependence, tolerance, withdrawal, and cognitive impairment.

iv. Atypical Anxiolytics : Compounds like busiprone (5-HT_{1A} partial agonist) that target alternative monoaminergic mechanisms.

2. Emerging Pharmacological Targets & Novel Drug Classes

To address treatment-refractory cases and avoid the drawbacks of traditional drugs, pharmaceutical research has focused on several novel neurochemical systems:

• Glutamatergic Modulators:

- NMDA receptor antagonists (such as ketamine and esketamine).

- NMDA partial agonists (such as D-cycloserine to augment exposure therapy). –

- Metabotropic glutamate receptor (mGluR) modulators.

• Neuropeptide System Agents:

- Corticotropin-releasing factor (CRF-1) antagonists.

- Neuropeptide Y (NPY) and oxytocin pathway modulators.

- Vasopressin (V_{1b} and V_{1a}) antagonists.

- Orexin receptor antagonists.

• Neuroactive Steroids:

- GABA-A / NMDA-active steroids (such as the intranasal neurosteroid aerosol

PH94B) designed for rapid, acute relief without systemic sedation.

• Cannabinoid System Modulators:

- Cannabidiol (CBD) and synthetic cannabinoids (like nabilone) interacting with CB1,

TRPV1, and 5-HT_{1A} receptors for anxiolytic effects without high-dose THC

panic risks.

• Advanced Serotonergic & Multimodal Agents:

- Melatonin agonists (agomelatine) and novel 5-HT_{1A} partial agonists (gepirone,

tandospirone).

- Serotonergic hallucinogens (like psilocybin and LSD) utilized in combination with

specialized psychotherapy.

1. Selective Serotonin Reuptake Inhibitors (SSRIs) & Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

• Advantages:

- They are non-addictive and serve as the standard,

- long-term foundation for managing anxiety disorders.

- They help treat overlapping conditions like depression very effectively.

• Disadvantages:

- They take several weeks to build up and begin working.

- They can cause disruptive physical side effects, most notably sexual dysfunction

2. Benzodiazepines (GABA-A Agonists)

• Advantages:

- They provide extremely rapid, powerful relief during severe panic attacks or acute

stress spikes.

- They are very effective for short-term control

• Disadvantages:

- They carry high risks of tolerance, chemical dependence, and severe withdrawal

symptoms if stopped abruptly

- They cause heavy side effects like drowsiness, cognitive clouding, and motor

impairment, making them poor choices for long-term daily management.

3. Atypical Anxiolytics (e.g., Busiprone)

• Advantages:

- They have a lower risk profile, lack the dependency issues of benzodiazepines, and

are safer for older adults.

• Disadvantages:

- They have a delayed onset of action and are often less potent for severe or acute

anxiety symptoms.

4. Emerging Rapid-Action Modulators (e.g., Ketamine / Glutamate Targets)

• Advantages:

- They work drastically faster than traditional daily antidepressants, offering relief in

hours or days instead of weeks

- They show promise for individuals whose anxiety has resisted all other standard

medications.

• Disadvantages:

- They usually require clinical supervision (such as monitored infusions) and are not

casual take-home pills

- Long-term safety and standard dosing protocols for anxiety are still being

researched.

Therapeutic Limitations

Current treatment strategies for anxiety disorders face several clinical and logistical barriers:

• Incomplete Response and Refractoriness : Only about 60% to 85% of patients experience a clinical response (at least a 50% symptom improvement) to standard biological and psychological treatments, and only around half of responders achieve full recovery. Approximately one-third of individuals suffer from treatment-refractory anxiety.
• Side Effect Profiles and Safety Concerns : First-line medications like Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) can cause durable adverse effects such as sexual dysfunction. Benzodiazepines, while fast-acting, carry risks of tolerance, physiological dependence, abuse potential, withdrawal symptoms, and severe cognitive or motor side effects, disqualifying them as first-line monotherapies.
• Lack of De Novo Drug Development : Very few pharmaceutical compounds have been engineered de novo specifically for anxiety disorders; most existing treatments were originally approved for major depressive disorder (MDD) or other conditions and later adapted.
• Methodological Flaws in Clinical Research : Clinical evaluations of newer agents have frequently been hampered by flawed trial designs, including small sample sizes, a lack of robust control groups, or failure to compare novel treatments directly against well-established standards like SSRIs or benzodiazepines.

Emerging Drug Targets

To overcome the limitations of traditional monoaminergic (serotonin/norepinephrine) and GABAergic agents, recent pharmaceutical research has shifted toward alternative neurochemical systems and pathways:

• Glutamate System Modulators : Because glutamate is the primary excitatory neurotransmitter, researchers have investigated metabotropic glutamate receptor (mGluR) modulators, NMDA receptor antagonists (such as ketamine and esketamine), and NMDA partial agonists (like D-cycloserine to augment exposure therapy) to rapidly influence fear processing circuits.
• Neuropeptide Pathways : Investigators are exploring non-traditional signaling molecules implicated in stress and fear regulation, including oxytocin, neuropeptide Y (NPY), vasopressin (V1b and V1a antagonists), corticotropin-releasing factor (CRF-1) antagonists, and orexin receptor antagonists.
• Neuroactive Steroids : Compounds acting directly on GABA-A, NMDA, and glutamate transcription systems—such as the intranasal neurosteroid aerosol PH94B—are being studied for rapid, acute relief during performance or social anxiety challenges without systemic sedative burdens. • Cannabinoid Receptors: Cannabidiol (CBD) and synthetic cannabinoids (like nabilone) are being evaluated for anxiolytic properties mediated through CB1, TRPV1, and 5-HT_{1A} receptor interactions, addressing limbic blood flow hyperactivity without the anxiogenic/panicogenic risks associated with high-dose delta-9-tetrahydrocannabinol (THC).
• Cannabinoid Receptors : Cannabidiol (CBD) and synthetic cannabinoids (like nabilone) are being evaluated for anxiolytic properties mediated through CB1, TRPV1, and 5-HT_{1A} receptor interactions, addressing limbic blood flow hyperactivity without the anxiogenic/panicogenic risks associated with high-dose delta-9-tetrahydrocannabinol (THC).
• Novel Serotonergic and Multimodal Agents : Exploration continues into specific receptor modulators, such as 5- HT_{1A} partial agonists (e.g., gepirone, tandospirone), 5-HT_{3} or 5-HT_{6} antagonists, melatonin agonists (agomelatine), and even serotonergic hallucinogens (like psilocybin and LSD) administered alongside psychotherapy for severe anxiety.

Gender-Specific Physiological Impacts of Chronic Stress and Panic Responses

A. Female Reproductive Axis Disruption (HPA-HPG Axis Interaction): In females, recurrent panic attacks trigger an acute 'fight-or-flight' response, elevating systemic cortisol levels and acutely spiking blood glucose concentration for immediate energy mobilization. Chronic activation of this pathway over-activates the Hypothalamic Pituitary-Adrenal (HPA) axis, subsequently suppressing the Hypothalamic-Pituitary-Gonadal (HPG) axis. This hormonal dysregulation impairs gonadotropin-releasing hormone (GnRH) pulsatility, leading to delayed ovulation and secondary menstrual irregularities (e.g., oligomenorrhea or amenorrhea).

B. Male Hepatic and Metabolic Dysfunctions (Gut-Liver Axis & Cortisol Dynamics):

In males, prolonged exposure to psychological stress significantly degrades hepatic metabolic functions. Chronic cortisol surge accelerates gluconeogenesis and hepatic glycogenolysis, worsening systemic insulin resistance. Furthermore, stress-induced oxidative stress causes lipid accumulation within hepatocytes, contributing to Non-Alcoholic Fatty Liver Disease (NAFLD). Elevated inflammation via the gut-liver axis along with suppressed testosterone levels further diminishes hepatic lipid clearance, elevating the risk of chronic liver dysfunction and metabolic syndrome.

CONCLUSION

Anxiety disorders remain among the most prevalent, disabling, and comorbid psychiatric conditions globally. Despite extensive knowledge of brain fear-circuitry, translating neurobiological findings into novel, FDA-approved medications has lagged significantly behind fields like depression and schizophrenia. Because a substantial portion of patients remain treatment-resistant or vulnerable to high relapse rates, future advancements depend heavily on looking beyond traditional comfort zones. Progress will likely rely on expanding research into novel pathways—such as glutamatergic modulators, neuropeptides, and neurosteroids—alongside personalized, multidisciplinary approaches that integrate pharmacotherapy, targeted psychotherapies, and advanced biomarkers.

REFERENCES

1. Garakani, A., Murrough, J. W., Freire, R. C., et al. (2020). Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Frontiers in Psychiatry, 11, 595584.
2. Bandelow, B., Reitt, M., Röver, C., et al. (2015). Efficacy of treatments for anxiety disorders: a meta-analysis. International Journal of Clinical Psychopharmacology, 30 (4), 183–192.
3. Bystritsky, A. (2006). Treatment-resistant anxiety disorders. Molecular Psychiatry, 11 (9), 805–814.
4. Roy-Byrne, P. (2015). Treatment-refractory anxiety; definition, risk factors, and treatment challenges. Dialogues in Clinical Neuroscience, 17 (2), 191–206.
5. Chen, T. R., Huang, H. C., Hsu, J. H., et al. (2019). Pharmacological and psychological interventions for generalized anxiety disorder in adults: a network meta-analysis. Journal of Psychiatric Research, 118, 73–83.
6. Liebowitz, M. R., Liebowitz, M. R., et al. (2016). Effect of as-needed use of intranasal PH94B on social and performance anxiety in individuals with social anxiety disorder. Depression and Anxiety, 33 (11), 1081–1089.
7. American Psychiatric Association (2009). Practice Guideline for the Treatment of Patients With Panic Disorder. Washington, DC: APA.
8. National Institute for Health and Care Excellence (NICE) (2011). Generalised Anxiety Disorder and Panic Disorder in Adults: Management (CG113).
9. Baldwin, D. S., Woods, R., Lawson, R., & Taylor, D. (2011). Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. British Journal of Psychiatry, 198 (4), 264–271.
10. Krystal, J. H., Sanacora, G., Blumberg, H., et al. (2002). Glutamate and GABA systems as targets for novel antidepressant and anxiolytic agents. Molecular Psychiatry, 7 (S1), S71–S80.
11. Goel, N., Workman, J. L., Lee, T. T., Innala, L., & Viau, V. (2014). Sex differences in the HPA axis. Comprehensive Physiology, 4 (3), 1121–1155